Minnesota Multidisciplinary Vasculitis Program
The Minnesota Multidisciplinary Vasculitis Program (M2VP) enrolls the 200th adult patient and 1st pediatric patient into the registry!
October 2021
Mission
To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to Phase 2 clinical trials in ANCA Vasculitis and Systemic Lupus Erythematosus.
Covered Diseases
- Systemic vasculitis:
- Small Vessel Vasculitis (ANCA-vasculitis, Anti-GBM disease, IgA Vasculitis)
- Medium Vessel vasculitis
- Large Vessel vasculitis
- Systemic Lupus Erythematosus
Goals
- Provide patients with complex systemic diseases with multidisciplinary care which is organized, streamlined and efficient.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with complex systemic diseases.
Multidisciplinary Team
Cardiology
Dermatology
Nephrology
- Shanthi Balani, MD
- Milind Junghare, MD
- Patrick Nachman, MD
- Michelle Rheault, MD (Pediatrics)
- Surabhi Thakar, MD
- Katti Woerner, DO
Otolaryngology (ENT)
Pulmonary
Rheumatology
- Mohanad Elfishawi, MBBCh, MS
- Parastoo Fazeli, MD
- Jacob Ijdo, PD, PhD
- Sahar Lotfi-Emran, MD, PhD
- Marta Michalska-Smith, MD
- Jerry Molitor, MD
- Luke Monteagudo, MD
- Daniel Mueller, MD
- Erik Peterson, MD
Clinical & Translational Research Team
- Tina Weiss, RN, BSN, PHN, Vasculitis & Lupus Program Nurse Navigator
- Amy Hanson, CCRC, Clinical Research Coordinator, Pediatrics
- Anael Kuperwajs Cohen, CCRC, Clinical Research Coordinator, Pediatrics
- Scott Rajala, CCRP, Clinical Research Coordinator
Ongoing Clinical Trials
ANCA Vasculitis
New Study Starting Soon!
Anti-GBM
A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Andrew Johnson, MD
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Aahd Kubbara, MD
Katie Pendleton, MD
Sami Safadi, MD
Study Coordinator
Nicolas Rauwolf | rauwo004@umn.edu
Systemic Lupus Erythematosus (SLE)
A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Principal Investigator
Parastoo Fazeli, MD
Co-Investigators
Jerry Molitor, MD, PhD
Patrick H. Nachman, MD
Marta Michalska Smith, MD
Study Coordinator:
Michelle Snyder, RN | snyde003@umn.edu
A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus
Principal Investigator
Patrick H. Nachman, MD
Co-Investigators
Parastoo Fazeli, MD
Marie Hu, MD
Nattawat Klomjit, MD
Study Coordinator:
Victoria Quinones, RN | quino072@umn.edu